the placebo group, and crofelemer continues to be found safe, with no apparent differences in adverse events between the treatment and placebo arms

The study, designated RISE, showed that a significantly higher percentage of patients receiving Lucentis achieved an improvement in vision of at least 15 letters on the eye chart at 24 months compared to those in the placebo group

In the per-protocol population, results showed that 65 percent of wounds treated with the high dose hit the endpoint, compared to 38 percent in the placebo group and 28 percent in the low-dose group

Efficacy after just one month was observed, including in multidrug-resistant TB patients, with a conversion rate of sputum smear of 78.3 percent in the treatment group vs. 0 percent in the placebo group

Inspire Pharmaceuticals Inc., of Durham, N.C., said findings published in the American Journal of Respiratory and Critical Care Medicine showed that cystic fibrosis patients, age 5 and older, receiving inhaled denufosol had better lung exhalation rates than those in the placebo group at the end of 24 weeks in a Phase III trial

ACR responses improved between week 12 and week 24, achieving up to 72 percent for ACR20, 44 percent for ACR50 and 30 percent of ACR70 compared to 32 percent for ACR20, 13 percent for ACR50 and 3 percent for ACR70 in the placebo group

ibuprofen demonstrated a 77 percent reduction in temperature compared with 32 percent for the placebo group

Agennix AG, of Frankfurt, Germany, reported at the International Sepsis Forum in Paris that its Phase II trial of talctoferrin for severe sepsis achieved its primary endpoint by reducing 28-day, all-cause mortality from 26.9 percent in the placebo group to 14.4 percent in the talactoferrin group

Genmab A/S, of Copenhagen, Denmark, reported interim results from a Phase II study of atumumab, its CD20-targeting antibody, in relapsing-remitting multiple sclerosis, which showed no dose-limiting toxicities, no unexpected safety findings and rates of infection that were comparable between the drug and placebo groups

After four weeks of dosing, average percent hemoglobin A1c was reduced by 1.15 in the 150-mg dose group (p = 0.036) and by 1.25 in the 300-mg dose group (p = 0.017), as compared with 0.49 in the placebo group...Baseline levels were 8.22 percent, 8.5 percent and 8.2 percent for the 150-mg, 300-mg and placebo groups, respectively

No statistically significant difference, however, was shown in opioid use between the Posidur or the Saber-placebo groups, the secondary endpoint...Subgroup data from adolescent patients, ages 12 to 18, showed a change in baseline in forced expiratory volume in one second of 112 mL for patients treated with denufosol compared to -10 mL for the placebo group at the 24-week endpoint

Helix BioPharma Corp., of Aurora, Ontario, reported results from a Phase II study of topical interferon alpha-2b cream in ano-genital warts showing that the proportion of patients with complete clearance of their baseline lesions during the eight-week treatment period, as well as the secondary efficacy endpoints, showed no statistically significant treatment effects between the drug and placebo groups

a reduction from a mean 43.5 events per hour of sleep to 27.0 events per hour in the placebo group

The PRX302 arm maintained the treatment benefit at six months with an average IPSS improvement of 8.9 (+/-6.7) points compared to 9.1 (+/-5.9) points at 90 days, while the placebo group showed a 21 percent worsening of symptoms at six months, with an IPSS improvement of 4.6 (+/-9.4) points compared to 5.8 (+/-5.4) points at 90 days

While the reductions were higher than in the placebo group, they did not reach a significant level

At week 12, the average daytime and nighttime asthma symptom score increased by 29 percent for the placebo group, while it decreased by 33 percent for QbG10-treated subjects

The high dose of SCV-07 prevented the onset of any ulcerative mucositis in 24 percent of patients at doses of radiation up to 50Gy (after approximately five weeks of treatment), while all patients in the placebo group suffered from ulcerative mucositis at 35Gy (after about 3.5 weeks of treatment

The results showed absolute improvement in MVO2 by 0.6 mL/kg/min in the treated group vs. 2.8 mL/kg/min worsening in the placebo group from baseline to six months, based on matched-pair analysis...For the entire cohort of patients, mean MVO2 improved from 16.6 mL/kg/min at baseline to 17.2 mL/kg/min at six months in cell-treated patients, and worsened from 19 mL/kg/min to 15.5 mL/kg/min in the placebo group

In addition, the data showed reductions in annualized relapse rate (ARR) compared to the placebo group over 96 weeks across the spectrum of baseline demographics and disease characteristics included in the CLARITY study...In the case of ALSFRS-R, the number of treatment failures totaled nine subjects (33 percent) in the placebo group, eight subjects (35 percent in the 50-mg/day group, four subjects (15 percent in the 150-mg/day group and two subjects (8 percent) in the 300-mg/day group